[Close]
- This page was created by volunteers like you!
- Help us make it even better. To learn more about contributing to MEpedia, click here.
- Join the movement
- Visit #MEAction to find support or take action. Donate today to help us improve and expand this project.
- Congratulations!
- MEpedia has got over 30 million views as of August 2022!
Suvorexant
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from Belsomra)
 | This article is a stub. |
Suvorexant or Belsomra (brand name) is an orexin receptor antagonist used to treat insomnia and improve sleep. Suvorexant acts as central nervous system depressant.[1][2]
Theory[edit | edit source]
Evidence[edit | edit source]
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Side effects of suvorexant include interaction with CYP3A inhibitors, increasing their effect.[1][3]
Costs and availability[edit | edit source]
Perscription only controlled drug. Generics not available.
See also[edit | edit source]
Learn more[edit | edit source]
- Belsomra - drugs.com
References[edit | edit source]
- ↑ Jump up to: 1.0 1.1 "Belsomra - FDA prescribing information, side effects and uses". Drugs.com. Retrieved January 16, 2022.
- ↑ Holmberg, Monica (July 10, 2015). "Belsomra". Pharmacy Times. Retrieved January 15, 2022.
- ↑ Liu, Mei T. (April 13, 2020). "Current and Emerging Therapies for Insomnia". Am J Manag Care. 26 (4 Suppl): S85–S90.
